All sponsors

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. $1177.HK

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS21
PHASE 3 / 2-37
RECRUITING18
READOUTS ≤12 MONTHS10
READOUT SLIPPED >6 MO27%

Delay Index: of 15 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. on the live radar map → 📅 $1177.HK readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
LM-108 injection+Penpulimab+ Oxaliplatin+Capecitabine
NCT06825494
P1/2RecruitingAdvanced Solid Tumor1942026-03
TQB2102 for injection
NCT06798207
P2RecruitingGynecological Tumors1702026-05
TQB2102 for injection
NCT06496490
P2RecruitingNon-Small Cell Lung Cancer2702026-06 (+8 mo)
TQB2102 for injection
NCT06452706
P2RecruitingBreast Cancer422026-06
Recombinant human activated coagulation factor VIII for injection
NCT06297655
P3Active, not recruitingHemophilia A602026-07 (+15 mo)
TQB2922 injection ± TAS-102 tablets
NCT07044908
P1/2RecruitingRAS/BRAF Wild Type Colorectal Cancer722026-07
TQB2102 for injection (7.5 mg) +Benmelstobart+Chemotherapy
NCT06767800
P2RecruitingGastroesophageal Adenocarcinoma2042026-09
TQB2868 injection
NCT06767813
P2RecruitingPancreatic Neoplasms802026-11 (+20 mo)
NCT06569524
NCT06569524
P2RecruitingNon-alcoholic Steatohepatitis1202026-12
TQC2938 injection
NCT06789289
P2Active, not recruitingChronic Obstructive Pulmonary Disease2562027-03-17 (-9 mo)
TQB2102 for injection
NCT06431490
P1/2RecruitingBiliary Tract Cancer1022027-05 (+24 mo)
TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)+Bevacizumab injection
NCT07653685
P1/2RecruitingColorectal Cancer712027-06
TQB2102 Injection
NCT07483684
P3Not yet recruitingHER2 IHC3+ Advanced Colorectal Cancer1422027-08
TQB2916 Injection
NCT06962267
P2RecruitingPancreatic Cancer502027-08
TQH3906 Capsule
NCT07406035
P2RecruitingPsoriatic Arthritis1562027-08
TQB2102 for injection
NCT07043725
P3RecruitingHER2-positive Breast Cancer5442027-09
TQH3906 capsules
NCT07724366
P3RecruitingPsoriasis4002027-09
TQB2930 injection+TQB2102 for injection
NCT07512583
P1/2RecruitingAdvanced Solid Tumor1782028-03
TQB2102 Injection
NCT07008976
P3RecruitingMetastatic Breast Cancer2462028-03
TQB2930+ chemotherapy
NCT07047365
P3RecruitingHER2-positive Advanced Breast Cancer4162028-06
TQB2102 for Injection
NCT07003074
P3RecruitingBreast Cancer6422029-07